BioXcel Therapeutics, Inc. Common Stock (BTAI)

Price$1.10

Value ScoreF

Growth ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-58.81%

Price vs S&P 500 (4W)-9.42%

VGM Score27.69

Market Capitalization$34.12M

All Metrics

Book Value / Share (Quarterly)$0.20

P/TBV (Annual)1.50x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)19.10%

Cash Flow / Share (Quarterly)$-2.12

Price vs S&P 500 (YTD)-39.10%

Gross Margin (TTM)36.32%

Net Profit Margin (TTM)-11078.53%

EPS (TTM)$-5.74

10-Day Avg Trading Volume0.83M

EPS Excl Extra (TTM)$-5.74

EPS (Annual)$-5.73

ROI (Annual)-97.56%

Gross Margin (Annual)74.45%

Net Profit Margin (5Y Avg)-108558.70%

Cash / Share (Quarterly)$0.63

Revenue Growth QoQ (YoY)22.62%

ROA (Last FY)-155.62%

Revenue Growth TTM (YoY)-63.28%

EBITD / Share (TTM)$-2.98

ROE (5Y Avg)-95.18%

Operating Margin (TTM)-7438.97%

Cash Flow / Share (Annual)$-2.58

P/B Ratio5.78x

P/B Ratio (Quarterly)32.92x

Net Income / Employee (Annual)$-2,410,200

EV / Revenue (TTM)172.40x

Net Interest Coverage (TTM)-3.39x

ROA (TTM)-201.53%

EPS Incl Extra (Annual)$-5.73

Current Ratio (Annual)0.83x

Quick Ratio (Quarterly)0.54x

3-Month Avg Trading Volume1.26M

52-Week Price Return-27.78%

Revenue / Employee (TTM)$23,400

Tangible BV / Share (Quarterly)$-1.39

P/S Ratio (Annual)53.15x

Asset Turnover (Annual)0.01x

52-Week High$8.08

Operating Margin (5Y Avg)-107317.30%

EPS Excl Extra (Annual)$-5.73

26-Week Price Return-50.89%

Quick Ratio (Annual)0.74x

13-Week Price Return-31.37%

Total Debt / Equity (Annual)1.21x

Current Ratio (Quarterly)0.62x

Enterprise Value$117.23M

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$22,100

Inventory Turnover (Annual)0.23x

Pretax Margin (Annual)-10887.38%

Cash / Share (Annual)$1.27

3-Month Return Std Dev89.83%

Net Income / Employee (TTM)$-2,597,700

ROE (Last FY)-215.83%

Net Interest Coverage (Annual)-3.65x

EPS Basic Excl Extra (Annual)$-5.73

Receivables Turnover (TTM)6.30x

Total Debt / Equity (Quarterly)16.41x

EPS Incl Extra (TTM)$-5.74

Receivables Turnover (Annual)3.53x

ROI (TTM)-126.96%

P/S Ratio (TTM)50.18x

Pretax Margin (5Y Avg)-108558.70%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$2.73

Price vs S&P 500 (52W)-52.14%

Year-to-Date Return-30.94%

5-Day Price Return-7.14%

EPS Normalized (Annual)$-5.73

ROA (5Y Avg)-135.84%

Net Profit Margin (Annual)-10887.38%

Month-to-Date Return-5.56%

Cash Flow / Share (TTM)$-7.34

EBITD / Share (Annual)$-4.11

Operating Margin (Annual)-7859.97%

LT Debt / Equity (Annual)1.21x

ROI (5Y Avg)-71.53%

LT Debt / Equity (Quarterly)16.41x

EPS Basic Excl Extra (TTM)$-5.74

P/B Ratio (Annual)7.84x

Inventory Turnover (TTM)0.76x

Pretax Margin (TTM)-11078.53%

Book Value / Share (Annual)$2.73

Price vs S&P 500 (13W)-39.62%

Beta0.37x

Revenue / Share (TTM)$0.03

ROE (TTM)-309.01%

52-Week Low$1.01

vGradeF

gGradeD

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.54est. -0.84

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.91

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
BTAIBioXcel Therapeutics, Inc. Common Stock	F	D	D	$1.10
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

BioXcel Therapeutics develops neuropsychiatric and immuno-oncology medicines using artificial intelligence platforms. Its FDA-approved commercial product, IGALMI, is a sublingual dexmedetomidine film for acute agitation associated with schizophrenia and bipolar I or II disorder in adults. The company is advancing additional pipeline candidates including BXCL701.